ADMA Biologics Study Shows Optimized IVIG Process Removes Impurities Linked to Thrombosis Risk
ADMA Biologics announced publication of peer-reviewed findings on its optimized intravenous immune globulin manufacturing process in Frontiers in Cardiovascular Medicine. Testing of three commercial-scale lots showed effective removal of impurities linked to thrombosis risk while preserving immunoglobulin quality. The